Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
iwCAR-T 2022
28 Apr–01 May 2022 | Tampa, FL / Online
The 4th International Workshop on CAR-T (iwCAR-T) took place on 28 April – 1 May 2022 in Tampa, FL, with VJHemOnc & VJOncology as official media partners. The workshop is a high-level discussion forum for research leaders in the field of CAR-T to share their perspectives on how to place this evolving understanding in a clinical context and thereby optimize clinical care. This year, a full day was dedicated to CAR-T therapy for solid cancers.
Session I: Emerging CARs and future challenges in solid tumors
Clinical perspective IO/TILs to BiTEs to TCR to CARs
Julian Molina Mayo Clinic, Rochester, MN
anti-HER2 CAR macrophages in solid tumors
Kim Reiss Binder University of Pennsylvania, Philadelphia, PA
Human iPSC-derived CAR-Ts with T-cell anti-tumor activity
Daniel Wang City of Hope, Duarte, CA
Session 2: GU cancers
PSMA-redirected Armored CAR-Ts for mCRPC
Vivek Narayan University of Pennsylvania, Philadelphia, PA
Armored CAR-T therapy in mPC
Joseph Fraietta University of Pennsylvania, Philadelphia, PA
P-PSMA-101 CAR-Ts for mCRPC
Susan Slovin Memorial Sloan Kettering Cancer Center, New York, NY
MAGE-A4 TCR for solid tumors
David Hong The University of Texas MD Anderson Cancer Center
Session 3: CAR-T clinical advances in solid tumors – lung
Landscape overview
Sandip Patel UC San Diego Health, San Diego, CA
TILs treatment for lung cancer
Sylvia Lee Fred Hutchinson Cancer Research Center, Seattle, WA
Overcoming barriers to CAR-T therapy in solid tumors
Shivani Srivastava Fred Hutchinson Cancer Research Center, Seattle, WA
‘Off-the-shelf’ PRBCs and iNKT cells
Melissa Johnson Sarah Cannon Research Institute, Nashville, TN
Session 4: Breast and ovarian cancers
CER T-cell technology for ovarian cancer
Jose Conejo-Garcia H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
BNT211: CLDN6 CAR-Ts & CARVac-based CAR-T in vivo expansion
Winfried Alsdorf University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Session 5: GI cancers
I-O to cell therapy; IO/T-VEC, BiTEs/TCRs
Joel Randolph Hecht UCLA Health, Los Angeles
Precision Promise: an adaptive phase 2/3 platform for drug development
Diane Simeone NYU Langone Health, New York City, NY
HuCART-meso cells in patients with pancreatic cancer
Mark O'Hara University of Pennsylvania, Philadelphia, PA
The future of logic-gated cell therapy
William Go A2 Biotherapeutics, Agoura Hills, CA
Session 6: Head/neck and CNS cancers
Cellular immunotherapy in head and neck cancers
Kedar Kirtane H. Lee Moffitt Cancer Center & Research Institute
Session 7: Melanoma, sarcomas
TILs for metastatic melanoma
Sylvia Lee Fred Hutchinson Cancer Research Center, Seattle, WA
The 4th International Workshop on CAR-T has been supported by:
